RxDoctor Payments Data

Paul Pelts

Psychiatry · New Orleans, LANPI 1477642676

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.4% of the total across 290 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 11.7% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,249in general payments, 2019–2025

Across 290 payments — averaging $21.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$734
  • Tris Pharma Inc$635
  • Otsuka America Pharmaceutical, Inc.$583
  • Supernus Pharmaceuticals, Inc.$567
  • Takeda Pharmaceuticals U.S.A., Inc.$508
  • Sunovion Pharmaceuticals Inc.$457
  • plus $3K from 17 others

What the payments were for

  • Food & beverage$6,21199%
  • Education$391%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,249 in reported general payments places this provider in the 90th percentile of 474 psychiatry providers in Louisiana.

See all psychiatry providers in Louisiana

Most prescribed under Part D

DrugClaimsCost to plans & patients
AuvelityDextromethorphan Hbr/Bupropion14$18,980
TrintellixVortioxetine Hydrobromide20$9,129
Venlafaxine Hcl ErVenlafaxine Hcl15$658
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine20$387
Lamotrigine35$362
Zolpidem Tartrate22$215
Bupropion XlBupropion Hcl29$215
Escitalopram Oxalate28$212
Paroxetine Hcl19$198
Trazodone Hcl27$198
Lurasidone Hcl12$149
Sertraline Hcl24$146
Aripiprazole21$146
Risperidone37$131
Clonazepam18$82

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Axsome Therapeutics, Inc.Auvelity$213$18,98014 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$508$9,12920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 474 psychiatry providers in Louisiana.

Other psychiatry in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →